Articles tagged with Dopamine
A new study reveals that iron deficiency in the brain's substantia nigra region may contribute to restless legs syndrome. Elevated levels of tyrosine hydroxylase (TH) were found in individuals with RLS, suggesting a link between cellular iron deficiency and dopamine regulation.
Researchers at Thomas Jefferson University have successfully converted adult human bone marrow stem cells into functional dopamine neurons using a novel growth factor-based approach. The newly differentiated cells expressed key markers of dopamine-producing cells and produced essential enzymes, offering a promising source for treating ...
Chronic exposure to pesticides like rotenone has been linked to Parkinson's disease pathology in monkeys. Exercise has shown potential in protecting against dopamine neuron loss and slowing disease progression in rats. Rotigotine, a new drug, may also offer neuroprotective properties.
A study by Emory University researchers found that brief reductions in blood oxygen levels during critical brain development can lead to long-lasting deficiencies in dopamine release and hyperactivity in juvenile rats. This discovery may help explain the development of ADHD and provide insights into potential treatments.
A study by Johannes Schwarz and colleagues tracked molecular changes in brains of Parkinson's patients over 7.5 years using SPECT to measure dopamine transporter binding, revealing a single exponential decline rather than linear loss. This advancement enables the development of individualized treatment for advanced Parkinson's patients.
Researchers found dopamine transporter injury in HIV dementia patients, suggesting a new direction for treatment. The study suggests that viral suppression may lead to recovery of deficits in the dopamine system.
Researchers found that monkeys with impaired dopamine receptors were more productive and accurate in their tasks, while those without the receptors procrastinated. The study uses a gene knockdown technique to deplete D2 receptors, leading to improved performance.
The study found that pramipexole and levodopa both significantly reduced motor complications and improved functional outcomes. However, pramipexole had a lower risk of dyskinesias and wearing off compared to levodopa. Both treatments provided similar quality of life, but long-term follow-up is needed to determine superiority.
Researchers at Vollum Institute found that dopamine molecules are released from midbrain nerve cells in a targeted manner, traveling to receptors within milliseconds. The study's findings suggest new therapeutic targets for Parkinson's disease and substance abuse.
Researchers used SPECT imaging to measure dopamine transporter binding in 18 adult ADHD patients. Those with high levels of binding showed significant improvement on Ritalin, while those with reduced binding did not respond to the drug.
Research at Vanderbilt University found that dopamine transmission increases in response to uncertain reward scenarios, such as gambling. The study used PET scanners to measure brain activity in nine human subjects and discovered localized regions showing increased or decreased dopamine release.
A study by OHSU found that methylphenidate, Ritalin, increases the effects of levodopa on dopamine levels, improving symptoms such as tapping and walking speeds. In contrast, paroxetine had no effect on physical symptoms but increased walking speed in Parkinson's patients.
Researchers used gene therapy to increase dopamine D2 receptor levels, reducing preference for alcohol and consumption by half in genetically predisposed rats. The treatment showed significant reductions in drinking preference and consumption in both groups, with the greatest effects observed within days of treatment.
Researchers presented promising results of a long-term gene therapy trial in monkeys with Parkinson's disease, showing improved symptoms with reduced levodopa doses. Genetic studies identified a new risk factor for early symptom onset linked to the GST gene, emphasizing the importance of both environmental and genetic factors in PD dev...
A new study found that infusing a molecule called glial cell line-derived neurotrophic factor (GDNF) directly into the brain improved Parkinson's disease symptoms in 41% of patients. The GDNF infusion resulted in significant increases in dopamine production and was sustained for at least two years, according to the research.
Researchers found that Tourette syndrome patients' brain activity during memory tasks normalized after receiving levodopa treatment. The study used functional magnetic resonance imaging and showed increased activity in certain brain regions, which decreased after treatment.
Researchers have discovered a chemical modification of the dopamine transporter that enables amphetamine-induced dopamine release. This finding may lead to the development of treatments for drug addiction by targeting this molecular mechanism.
Researchers discovered a protective protein, Wlds, that safeguards dopamine-axon connections in Parkinson's disease. The study revealed that while the protein protects axons, it does not prevent cell body damage, highlighting differences in degeneration processes.
A recent genetic study found a strong association between the dopamine receptor D1 gene and attention-deficit/hyperactivity disorder (ADHD). The study suggests that this gene variant may increase the risk of developing inattentive symptoms of ADHD. Further research is needed to confirm these findings, but the discovery provides new ins...
Researchers found that specific variants of dopamine transporter and receptor genes associated with higher dopamine levels in the brain facilitated smoking cessation. This study highlights the importance of genetic investigations beyond single gene effects.
A new study found that exposing pregnant rats to MDMA resulted in significant increases in dopamine neuron fibers in the frontal cortex, leading to potential behavioral changes. The study also revealed modest decreases in dopamine metabolism and reductions in serotonin levels, suggesting sex differences in vulnerability to MDMA's prena...
A study of 1,884 Parkinson's patients found that nine developed pathological gambling, with most taking high doses of dopamine agonists. The condition was often linked to financial problems and could be controlled with treatment changes.
A PET scan study found that only a combination of methylphenidate and a behavioral stimulus resulted in increased dopamine levels. The increases were associated with improved perception of the task as interesting and motivating.
A study using PET scans found that schizophrenics have elevated dopamine receptor levels in both basal forebrain and SN/VTA areas of the brain. Differences were observed in cortical dopamine levels, supporting the hypothesis of dysregulated neurotransmission leading to abnormal regulation of neurons.
A recent study suggests that I-123 Altropane SPECT imaging can detect dopamine deficiency in patients with drug-naïve ADHD. The study's results indicate a higher binding ratio of the radiopharmaceutical to dopamine transporters in ADHD patients, supporting the idea of a potential diagnostic tool.
Research supports the hypothesis that mesocortical dopamine function is impaired in schizophrenia, with decreased D2/3 receptor density associated with negative and general psychopathological symptoms. Age was also negatively correlated with D2/3 receptor density among controls.
A study found that a specific gene variant affects prefrontal brain function and response to amphetamine. People with the val/val variant had reduced prefrontal dopamine activity and less efficient information processing, while those with met/met had more efficient function but also faced cognitive decline when challenged.
Researchers monitored brain activity in rats to understand how cues contribute to drug relapse. They found that rapid dopamine release occurs in response to cues associated with cocaine, initiating drug-seeking behaviors. This study provides new insights into the neural mechanisms underlying cocaine addiction.
Researchers used genetically modified mice to understand cocaine's brain mechanisms, revealing the drug's actions go beyond dopamine and norepinephrine transporters. The findings suggest the serotonin system may also be a target for cocaine treatment.
Researchers at UNC Chapel Hill found a third transporter, the serotonin system, plays a role in cocaine's effects on the brain. The discovery brings medical science closer to effective therapies for treating cocaine addiction.
Researchers found that dopamine levels increased significantly before laboratory rats chose to get more cocaine, paralleling human addictive behavior. The findings suggest that real-time increases in dopamine may control drug-taking behaviors and inform treatment for cocaine addiction.
A two-year follow-up study shows participants with advanced PD experienced improvements in tremor, stiffness, slow movement, and balance. The new cell therapy, Spheramine, provided a source of increased dopamine production, maintaining initial gains up to 24 months post-treatment.
A new study reports remarkable improvements in motor skills and dopamine storage in five Parkinson's patients. The treatment, which administered GDNF directly into the brain, showed a 39% improvement in motor skills and 61% improvement in daily living activities.
Researchers found low-dose exposure to permethrin triggered a process with early onset and persistent effects, while high-level exposures had delayed effects. The study suggests that genetic predisposition may increase the risk of damage from pesticide exposure.
Researchers found cocaine users had lower dopamine and VMAT2 levels in their brains compared to non-users. Additionally, depressed cocaine users had lower VMAT2 levels than those without depression.
Researchers found that selegiline hydrochloride significantly increased smoking cessation rates among participants, with 45% quitting after 8 weeks of treatment. This suggests the MAO-B inhibitor may be an effective treatment for nicotine addiction.
Researchers found that individuals with two copies of the met form of the COMT gene had a more pronounced response to pain, while those with two copies of the val form reported less pain and fewer negative emotions. The study used PET brain imaging and controlled jaw pain to investigate the role of genetic variation in pain tolerance.
A new screening method uses glowing worms to test neuroprotective compounds, which may lead to new Parkinson's disease treatments. Researchers can selectively kill dopamine neurons in living worms using neurotoxins, and the green glow dims when they die.
Dr. Ted Fon, a renowned Parkinson's Disease researcher, has been awarded a significant grant by the Michael J. Fox Foundation to investigate the role of protein degradation in the disease. The grant aims to enhance understanding of parkin function and its potential impact on dopamine nerve cell death.
Researchers found a link between alcohol intake and endocannabinoid-like brain compounds in mice, suggesting a potential target for medication development. The study's findings parallel observations in humans, with age-dependent decline in alcohol preference and reduced CB1 receptor signaling.
Research reveals cocaine causes harm to brain cells that trigger feelings of pleasure, potentially explaining addiction and depression. The study found significant lower levels of dopamine neurons in cocaine users compared to non-users.
Researchers at Thomas Jefferson University have successfully converted human neural stem cells into dopamine-making neurons in a laboratory setting. Approximately 25% of the stem cells were able to produce the enzyme tyrosine hydroxylase, which is necessary for dopamine production. The breakthrough could potentially lead to the develop...
Dr. Francis White, a leading expert in neuropsychopharmacology, has received the prestigious MERIT Award from the National Institute on Drug Abuse. His research focuses on understanding the neurobiology of dopamine systems and their role in addiction, with implications for developing new treatments.
Researchers successfully used gene therapy to change the brain's circuitry in rats with Parkinson's disease, producing nearly 70% fewer symptoms. The treatment involves altering glutamate and GABA signaling pathways to protect dopamine neurons from deterioration.
A study by Johns Hopkins Medicine finds that Ecstasy use can cause severe brain dopamine deficits and potentially lead to parkinsonism in humans. The researchers administered MDMA to squirrel monkeys and observed significant neuronal injury.
Researchers found a common mutation in the DAT gene to be associated with trauma survivors who developed chronic PTSD, suggesting a genetic contribution to the disorder's development. The study implies that genetically determined variation in dopaminergic neurotransmission may play a role in shaping the pathological response to trauma.
A Rutgers University researcher found that dopamine loss causes brain connections to reorganize, leading to impaired motor control. The study suggests that this permanent change may explain why current treatments fail to restore complex movements in Parkinson's disease patients.
Researchers found that a drug mimicking dopamine effects reduces desire to smoke, while a drug impeding dopamine's effects increases puffing frequency. The study suggests dopamine plays a crucial role in cigarette smoking addiction.
The Society of Nuclear Medicine announced its Image of the Year, showcasing an innovative PET scan for detecting lung cancer in a patient with dermatomyositis. The image also highlights a groundbreaking study on dopamine transporters in mouse brains using ultra-high resolution SPECT.
Dopamine and ethanol act through independent mechanisms to produce a common cellular response sustaining voluntary drinking behavior in rats. The study suggests synergy between dopamine D2 and adenosine A2 receptors creates hypersensitivity to ethanol and beta gamma dimers are required for sustained drinking.
Researchers identify Beta-gamma dimer as key molecule in the brain's response to alcohol, which amplifies dopamine release and contributes to cravings. Blocking this molecule may prevent excessive drinking and provide a novel target for medications.
Researchers used PET scans to measure changes in dopamine during food and neutral stimulation. Food stimulation increased dopamine in the dorsal striatum but not in the ventral striatum, suggesting a role in food motivation beyond reward effects.
Researchers found that mere sight or smell of food spikes levels of dopamine in the brain, a key player in addiction. The study also showed that certain medications can amplify weak dopamine signals, potentially helping with weight management.
Researchers found that ropinirole slowed the loss of dopamine function in early stages of Parkinson's disease by over 30 percent compared to levodopa. The REAL-PET study used positron emission tomography (PET) brain imaging and showed significant slowing of dopamine loss, which could lead to a better quality of life for patients.
A new study found that alcohol and nicotine interact in the brain's dopamine system, suggesting a link between the two addictive behaviors. Rodent studies showed that combining alcohol and nicotine increased dopamine release, while blocking nicotinic effects with mecamylamine reduced alcohol's pleasurable effects.
Two women with Parkinson's disease experienced hair loss while on dopamine agonists pramipexole and ropinirole. After discontinuing these medications and switching to new treatments, their hair growth resumed in both cases.
A study by Brookhaven National Laboratory found that individual variation in dopamine release affects Ritalin's efficacy in treating attention/hyperactivity disorder. The study suggests that patients with low dopamine cell activity may not respond to the drug, even if it blocks dopamine transporters.
Researchers used C.elegans to study molecular mechanisms of dopamine neuron degeneration in Parkinson's disease. The study found that exposure to a neurotoxin, 6-OHDA, caused rapid death of dopamine neurons, and blocking dopamine transporter function eliminated the toxic effect.
Researchers have linked two key brain abnormalities in schizophrenia, including reduced frontal lobe activation and abnormal dopamine release, suggesting a common pathophysiological mechanism. The study suggests that antipsychotic drugs may target the wrong area, leading to an excess of dopamine activity.
Researchers believe that a single deficit in context processing, impaired by declining dopamine levels, may explain age-related cognitive declines. Studies showed older adults performed worse on tests requiring context processing, while younger adults did better.